Akebia extends COO Dahan and CLO Hadas separation dates to 2024

Akebia Therapeutics, Inc.

COO Michel Dahan termination extended to March 22, 2024 (could extend to Sept 22, 2024 under certain events).
Chief Legal Officer Nicole Hadas termination extended to Oct 6, 2023 (could extend to March 22, 2024).
Both changes are amendments to retention/separation agreements from Nov 2022 and May 2023.
Extensions are part of the workforce reduction announced May 9, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nicole R. Hadas

Senior Vice President, Chief Legal Officer and Corporate Secretary

AKBA · Akebia Therapeutics, Inc.

Effective: 2023-10-06
Filed: August 1, 2023, 7:59 PM ET

On July 26, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to October 6, 2023, and, in the event of certain specified events, the effective date of her termination may extend to March 22, 2024

Departed

Michel Dahan

Chief Operating Officer

AKBA · Akebia Therapeutics, Inc.

Effective: 2024-03-22
Filed: August 1, 2023, 7:59 PM ET

On July 26, 2023, the Company and Mr. Dahan agreed to further extend the effective date of his termination to March 22, 2024, and, in the event of certain specified events, the effective date of his termination may extend to September 22, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole R. Hadas departed as Senior Vice President, Chief Legal Officer and Corporate Secretary at Akebia Therapeutics, Inc..

Action: extended termination date to
Role: Senior Vice President, Chief Legal Officer and Corporate Secretary

Exact text from the filing

On July 26, 2023, the Company and Ms. Hadas agreed to further extend the effective date of her termination to October 6, 2023, and, in the event of certain specified events, the effective date of her termination may extend to March 22, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michel Dahan departed as Chief Operating Officer at Akebia Therapeutics, Inc..

Action: extended termination date to
Role: Chief Operating Officer

Exact text from the filing

On July 26, 2023, the Company and Mr. Dahan agreed to further extend the effective date of his termination to March 22, 2024, and, in the event of certain specified events, the effective date of his termination may extend to September 22, 2024

View on SEC.gov

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.